133 related articles for article (PubMed ID: 16805911)
1. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
[TBL] [Abstract][Full Text] [Related]
2. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
Duong HK; Sekeres MA
Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.
Pawinska-Wasikowska K; Czogala M; Skoczen S; Surman M; Rygielska M; Ksiazek T; Pac A; Wieczorek A; Skalska-Sadowska J; Samborska M; Wachowiak J; Chaber R; Tomaszewska R; Szczepanski T; Zielezinska K; Urasinski T; Moj-Hackemer M; Kalwak K; Kozlowska M; Irga-Jaworska N; Balwierz W; Bukowska-Strakova K
Front Immunol; 2023; 14():1268993. PubMed ID: 38187390
[TBL] [Abstract][Full Text] [Related]
4. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review.
Adkins BD; Noland DK; Slone T; Sadanand A
J Clin Apher; 2024 Jun; 39(3):e22116. PubMed ID: 38647036
[TBL] [Abstract][Full Text] [Related]
6. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
FitzGerald DJ; Wayne AS; Kreitman RJ; Pastan I
Cancer Res; 2011 Oct; 71(20):6300-9. PubMed ID: 21998010
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.
Satomaa T; Pynnönen H; Aitio O; Hiltunen JO; Pitkänen V; Lähteenmäki T; Kotiranta T; Heiskanen A; Hänninen AL; Niemelä R; Helin J; Kuusanmaki H; Vänttinen I; Rathod R; Nieminen AI; Yatkin E; Heckman CA; Kontro M; Saarinen J
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38561023
[TBL] [Abstract][Full Text] [Related]
9. Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas.
Kyriakidis I; Mantadakis E; Stiakaki E; Groll AH; Tragiannidis A
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291806
[TBL] [Abstract][Full Text] [Related]
10. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
Kyriakidis I; Vasileiou E; Rossig C; Roilides E; Groll AH; Tragiannidis A
J Fungi (Basel); 2021 Mar; 7(3):. PubMed ID: 33807678
[TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.
Niktoreh N; Lerius B; Zimmermann M; Gruhn B; Escherich G; Bourquin JP; Dworzak M; Sramkova L; Rossig C; Creutzig U; Reinhardt D; Rasche M
Haematologica; 2019 Jan; 104(1):120-127. PubMed ID: 30093401
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
13. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.
Guest EM; Aplenc R; Sung L; Raimondi SC; Hirsch BA; Alonzo TA; Gerbing RB; Wang YJ; Kahwash SB; Heerema-McKenney A; Meshinchi S; Gamis AS
Blood; 2017 Aug; 130(7):943-945. PubMed ID: 28674028
[No Abstract] [Full Text] [Related]
14. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
Stasi R
Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
